ciprofloxacin has been researched along with Bacterial Pneumonia in 103 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors determined the pharmacokinetic parameters of a new immediate-release ciprofloxacin suspension in tube-fed intensive care patients with bacterial pneumonia, to compare two dosage regimens: 500 mg b." | 9.10 | Pharmacokinetic parameters of ciprofloxacin (500 mg/5 mL) oral suspension in critically ill patients with severe bacterial pneumonia: a comparison of two dosages. ( Allaouchiche, B; Boselli, E; Breilh, D; Chassard, D; Debon, R; Duflo, F; Saux, MC, 2002) |
| "After enrollment in a Food and Drug Administration approved protocol, the pharmacokinetic profiles of ciprofloxacin (CIP) administered to 18 children with cystic fibrosis (ages 5 to 17 years) were studied at steady state after sequentially administered intravenous (10 mg/kg every 8 h) and oral (20 mg/kg every 12 h) doses." | 9.08 | Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. ( Church, DA; Echols, RM; Kuhn, RJ; Lettieri, JT; Miles, MV; Rubio, TT, 1997) |
| " ceftazidime/tobramycin in hospitalized pediatric cystic fibrosis patients with an acute pulmonary exacerbation associated with P." | 9.08 | Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. ( Church, DA; Echols, RM; Haverstock, DC; Kanga, JF; Kuhn, RJ; Painter, BG; Perroncel, RY; Rubio, TT; Spohn, WA; Stevens, JC; Thurberg, BE, 1997) |
| "We report a rare case of torsade de pointes, a polymorphic ventricular tachycardia associated with QT interval prolongation, caused by intravenous ciprofloxacin given for pneumonia in a 22-year-old healthy Marine." | 7.73 | Ciprofloxacin-induced torsade de pointes. ( Flanagan, MC; Haigney, MC; Mitchell, ES, 2006) |
| "The efficacies of gatifloxacin and moxifloxacin were assessed in a BALB/c mouse model of pneumonic tularemia and compared with the efficacy of ciprofloxacin." | 7.73 | Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin. ( Brooks, TJ; Lever, MS; Piercy, T; Simpson, AJ; Steward, J, 2006) |
| "This study was performed to examine the ability of ciprofloxacin (CPFX) to suppress the inflammation associated with lipopolysaccharide (LPS) and an inflammatory cytokine in gram-negative bacterial pneumonia." | 7.73 | Effect of ciprofloxacin on levels of lipopolysaccharide and cytokines in experimentally induced gram-negative bacterial pneumonia in mice. ( Kamiya, S; Kawai, S; Kobayashi, O; Nakagawa, T; Sakayori, S, 2006) |
| "To assess the value of prophylactic ciprofloxacin in reducing the incidence of neutropenic fever in men receiving intensive chemotherapy for germ cell tumours, we reviewed the case notes of 88 consecutive patients treated between January 1986 and December 1992." | 7.69 | Chemotherapy for germ cell tumours: prophylactic ciprofloxacin reduces the incidence of neutropenic fever. ( Counsell, R; Pratt, J; Williams, MV, 1994) |
| " The purpose of this prospective study was to (i) develop a pharmacokinetic (PK) model to be utilized for therapeutic drug monitoring (TDM) of ciprofloxacin and (ii) evaluate current ciprofloxacin dosing regimens for pneumonias in cystic fibrosis (CF) patients." | 6.70 | Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. ( Aminimanizani, A; Beringer, PM; Gill, MA; Jelliffe, R; Louie, SG; Montgomery, MJ; Shapiro, BJ, 2001) |
| " Mild or moderate adverse events (AE) occurred in 13/153 (8." | 6.69 | Efficacy and safety of high dose intravenous ciprofloxacin in the treatment of bacterial pneumonia. Italian Ciprofloxacin Study Group. ( Curti, ME; Mazzei, T; Periti, P, 1998) |
| "The authors determined the pharmacokinetic parameters of a new immediate-release ciprofloxacin suspension in tube-fed intensive care patients with bacterial pneumonia, to compare two dosage regimens: 500 mg b." | 5.10 | Pharmacokinetic parameters of ciprofloxacin (500 mg/5 mL) oral suspension in critically ill patients with severe bacterial pneumonia: a comparison of two dosages. ( Allaouchiche, B; Boselli, E; Breilh, D; Chassard, D; Debon, R; Duflo, F; Saux, MC, 2002) |
| "The efficacy of ciprofloxacin was studied in the treatment of 22 patients with hospital infection of the lower respiratory tract: 10 patients with nosocomial pneumonia, 8 with exacerbation of chronic obstructive bronchitis, 3 with exacerbation of mucoviscidosis and 1 with bronchiectasis." | 5.08 | [Effectiveness of ciprofloxacin in the treatment of hospital infections of the lower respiratory tract]. ( Avdeev, SN; Belevskiĭ, AS; Chuchalin, AG; Novikov, IuK, 1997) |
| "After enrollment in a Food and Drug Administration approved protocol, the pharmacokinetic profiles of ciprofloxacin (CIP) administered to 18 children with cystic fibrosis (ages 5 to 17 years) were studied at steady state after sequentially administered intravenous (10 mg/kg every 8 h) and oral (20 mg/kg every 12 h) doses." | 5.08 | Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. ( Church, DA; Echols, RM; Kuhn, RJ; Lettieri, JT; Miles, MV; Rubio, TT, 1997) |
| " ceftazidime/tobramycin in hospitalized pediatric cystic fibrosis patients with an acute pulmonary exacerbation associated with P." | 5.08 | Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. ( Church, DA; Echols, RM; Haverstock, DC; Kanga, JF; Kuhn, RJ; Painter, BG; Perroncel, RY; Rubio, TT; Spohn, WA; Stevens, JC; Thurberg, BE, 1997) |
| " For primary prophylaxis, short-term antibiotic treatment (oral norfloxacin or ciprofloxacin) is indicated in cirrhotic patients (with or without ascites) admitted with gastrointestinal haemorrhage (variceal or non-variceal)." | 4.84 | [Bacterial infections in liver cirrhosis]. ( Farkas, A; Papp, M; Tornai, I; Udvardy, M, 2007) |
| "We report a rare case of torsade de pointes, a polymorphic ventricular tachycardia associated with QT interval prolongation, caused by intravenous ciprofloxacin given for pneumonia in a 22-year-old healthy Marine." | 3.73 | Ciprofloxacin-induced torsade de pointes. ( Flanagan, MC; Haigney, MC; Mitchell, ES, 2006) |
| "The efficacies of gatifloxacin and moxifloxacin were assessed in a BALB/c mouse model of pneumonic tularemia and compared with the efficacy of ciprofloxacin." | 3.73 | Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin. ( Brooks, TJ; Lever, MS; Piercy, T; Simpson, AJ; Steward, J, 2006) |
| "This study was performed to examine the ability of ciprofloxacin (CPFX) to suppress the inflammation associated with lipopolysaccharide (LPS) and an inflammatory cytokine in gram-negative bacterial pneumonia." | 3.73 | Effect of ciprofloxacin on levels of lipopolysaccharide and cytokines in experimentally induced gram-negative bacterial pneumonia in mice. ( Kamiya, S; Kawai, S; Kobayashi, O; Nakagawa, T; Sakayori, S, 2006) |
| "To assess the value of prophylactic ciprofloxacin in reducing the incidence of neutropenic fever in men receiving intensive chemotherapy for germ cell tumours, we reviewed the case notes of 88 consecutive patients treated between January 1986 and December 1992." | 3.69 | Chemotherapy for germ cell tumours: prophylactic ciprofloxacin reduces the incidence of neutropenic fever. ( Counsell, R; Pratt, J; Williams, MV, 1994) |
| "The efficacy and safety of Cifran OD, a new dosage form of ciprofloxacin with prolonged action were studied in the treatment of patients with bronchopulmonary infection (n=23)." | 2.71 | [Therapy of bronchopulmonary infection in smokers]. ( Orlov, VA; Shenderovich, VA; Smirnova, LB; Sokolova, VI; Surkova, IuV, 2004) |
| " The purpose of this prospective study was to (i) develop a pharmacokinetic (PK) model to be utilized for therapeutic drug monitoring (TDM) of ciprofloxacin and (ii) evaluate current ciprofloxacin dosing regimens for pneumonias in cystic fibrosis (CF) patients." | 2.70 | Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. ( Aminimanizani, A; Beringer, PM; Gill, MA; Jelliffe, R; Louie, SG; Montgomery, MJ; Shapiro, BJ, 2001) |
| " Mild or moderate adverse events (AE) occurred in 13/153 (8." | 2.69 | Efficacy and safety of high dose intravenous ciprofloxacin in the treatment of bacterial pneumonia. Italian Ciprofloxacin Study Group. ( Curti, ME; Mazzei, T; Periti, P, 1998) |
| "These superinfections occurred in mechanically ventilated, postoperative cardiac surgical patients after 13 days in the intensive care unit (ICU)." | 2.69 | Outbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective, randomized study. ( Brase, R; Heimesaat, M; Kljucar, S; Manhold, C; Timm, J; von Pritzbuer, E; von Rolbicki, U, 1998) |
| "ciprofloxacin was at least equivalent to imipenem in terms of bacteriological eradication and clinical response." | 2.69 | Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia. ( Caldwell, JW; Johnson, RH; Singh, S, 1999) |
| " The once daily dosage of fleroxacin [400 mg once daily intravenously (i." | 2.68 | Quinolones in everyday clinical practice: respiratory tract infections and nosocomial pneumonia. ( Marklein, G, 1996) |
| "The lower respiratory tract infections caused by E." | 2.68 | [The clinical manifestation and drug sensitive tests of lower respiratory tract infection by enterobacter cloacae. The Pulmonary Infection and Fibrosis Group, Thoracic Society Shanghai Medical Association]. ( , 1997) |
| "For levofloxacin-treated CAP patients with P." | 2.43 | Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience. ( Davis, NB; Kahn, J; Tennenberg, AM; Wu, SC, 2006) |
| "Anthrax is a zoonotic disease caused by Bacillus anthracis." | 2.40 | [Pulmonary anthrax]. ( Debord, T; Vidal, D, 1998) |
| "The aims of the study were to develop a population pharmacokinetic model of ciprofloxacin (CPX) in the elderly patients and to examine the impact of patient-dependent variables on pharmacokinetic parameter values of this drug." | 1.40 | Population pharmacokinetic analysis of ciprofloxacin in the elderly patients with lower respiratory tract infections. ( Cios, A; Grodzicki, T; Szymura-Oleksiak, J; Wyska, E, 2014) |
| "Tularemia is a worldwide zoonosis caused by Francisella tularensis." | 1.38 | Cavitary pneumonia and skin lesions. ( Alvela-Suárez, L; Belhassen-Garcia, M; Carpio-Pérez, A; Fraile-Alonso, Mdel C; Pardo-Lledias, J; Velasco-Tirado, V, 2012) |
| "Moxifloxacin is a respiratory fluoroquinolone with a community acquired pneumonia indication." | 1.35 | Fluoroquinolone resistance during 2000-2005: an observational study. ( Lindsell, C; Ryan, RJ; Sheehan, P, 2008) |
| "The present case showed once again that nocardiosis is not limited to patients with immunodeficiencies." | 1.34 | [Pulmonary nocardiosis with trimethoprime/sulphamethoxazole-resistant Nocardia paucivorans in a patient with no signs of immunosuppression]. ( Eder, W; Häussinger, K; Hoffmann, H; King, B; Markus, A; Morresi-Hauff, A; Philipp, E; Steffen, H; Weber, N; Wegerle, S, 2007) |
| " The probabilities of each drug and dosing regimen in achieving pharmacodynamic targets were calculated." | 1.33 | Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program. ( Kuti, JL; Nicolau, DP; Sun, HK, 2005) |
| "The incidence of nosocomial infections in patients after ICAAS fell from 78." | 1.32 | Prevention of nosocomial lower respiratory tract infections in patients after intracranial artery aneurysm surgery with a short course of antimicrobials. ( Beovic, B; Bosnjak, R; Cizman, M; Hergouth-Krizan, V; Matos, B; Mueller-Premru, M; Seme, K, 2003) |
| " Dosing regimens were chosen to obtain a comparable area under the concentration-time curve from 0 to infinity/MIC ratio of 27." | 1.31 | Differential selection of multidrug efflux mutants by trovafloxacin and ciprofloxacin in an experimental model of Pseudomonas aeruginosa acute pneumonia in rats. ( Carbon, C; Chau, F; Dautrey, S; Faurisson, F; Join-Lambert, OF; Köhler, T; Michéa-Hamzehpour, M; Pechère, J; Vissuzaine, C, 2001) |
| "Ciprofloxacin was applied in four different diffusion sources (1, 3, 10 and 30 microg) on a single strip, the M-strip, and used." | 1.31 | MIC determination of fusidic acid and of ciprofloxacin using multidisk diffusion tests. ( Kronvall, G, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (3.88) | 18.7374 |
| 1990's | 33 (32.04) | 18.2507 |
| 2000's | 48 (46.60) | 29.6817 |
| 2010's | 15 (14.56) | 24.3611 |
| 2020's | 3 (2.91) | 2.80 |
| Authors | Studies |
|---|---|
| Gou, S | 1 |
| Li, B | 1 |
| Ouyang, X | 1 |
| Ba, Z | 1 |
| Zhong, C | 1 |
| Zhang, T | 1 |
| Chang, L | 1 |
| Zhu, Y | 1 |
| Zhang, J | 1 |
| Zhu, N | 1 |
| Zhang, Y | 1 |
| Liu, H | 1 |
| Ni, J | 1 |
| Lan, J | 1 |
| Ma, Q | 1 |
| Li, J | 1 |
| Shao, C | 1 |
| Shan, A | 1 |
| Begbey, A | 1 |
| Guppy, JH | 1 |
| Mohan, C | 1 |
| Webster, S | 1 |
| Duhil de Bénazé, G | 1 |
| Desselas, E | 1 |
| Houdouin, V | 1 |
| Mariani-Kurkdjian, P | 1 |
| Kheniche, A | 1 |
| Dauger, S | 1 |
| Poncelet, G | 1 |
| Gaschignard, J | 1 |
| Levy, M | 1 |
| Alhabshan, RN | 1 |
| Mansour, TN | 1 |
| Harent, S | 1 |
| Vuotto, F | 1 |
| Wallet, F | 1 |
| Flateau, C | 1 |
| Chopin, MC | 1 |
| Faure, K | 1 |
| Guery, B | 2 |
| Domínguez-Herrera, J | 1 |
| Velasco, C | 1 |
| Docobo-Pérez, F | 2 |
| Rodríguez-Martínez, JM | 2 |
| López-Rojas, R | 1 |
| Briales, A | 1 |
| Pichardo, C | 2 |
| Díaz-de-Alba, P | 1 |
| Rodríguez-Baño, J | 1 |
| Pascual, A | 2 |
| Pachón, J | 2 |
| Sun, Z | 1 |
| Shi, J | 1 |
| Liu, C | 1 |
| Jin, Y | 1 |
| Li, K | 1 |
| Chen, R | 1 |
| Jin, S | 1 |
| Wu, W | 1 |
| Cios, A | 1 |
| Wyska, E | 1 |
| Szymura-Oleksiak, J | 1 |
| Grodzicki, T | 1 |
| Wang, JY | 1 |
| Lee, CH | 1 |
| Yu, MC | 1 |
| Lee, MC | 1 |
| Lee, LN | 2 |
| Wang, JT | 1 |
| Marquart, JD | 1 |
| Clifford, R | 1 |
| Yayan, J | 1 |
| Ghebremedhin, B | 1 |
| Rasche, K | 1 |
| García, I | 1 |
| Pachón-Ibañez, ME | 1 |
| Martínez-Martínez, L | 1 |
| Chono, S | 1 |
| Tanino, T | 1 |
| Seki, T | 1 |
| Morimoto, K | 1 |
| Turtle, L | 1 |
| Wey, E | 1 |
| James, E | 1 |
| Oztürk, O | 1 |
| Akçam, Z | 1 |
| Sahin, U | 1 |
| Bircan, A | 1 |
| Akkaya, A | 1 |
| Yayli, G | 1 |
| Nakamura, S | 1 |
| Yanagihara, K | 2 |
| Araki, N | 1 |
| Morinaga, Y | 1 |
| Izumikawa, K | 1 |
| Seki, M | 1 |
| Kakeya, H | 2 |
| Yamamoto, Y | 1 |
| Kamihira, S | 1 |
| Kohno, S | 2 |
| Sugimoto, S | 1 |
| Yoshimura, Y | 1 |
| Tachikawa, N | 1 |
| Belhassen-Garcia, M | 1 |
| Velasco-Tirado, V | 1 |
| Alvela-Suárez, L | 1 |
| Fraile-Alonso, Mdel C | 1 |
| Carpio-Pérez, A | 1 |
| Pardo-Lledias, J | 1 |
| Papanicolas, LE | 1 |
| Holds, JM | 1 |
| Bak, N | 1 |
| Issaoui, S | 1 |
| Maoulainine, FM | 1 |
| Elidrissi, NS | 1 |
| Sorra, N | 1 |
| Chabaa, L | 1 |
| Aboussad, A | 1 |
| Durdu, B | 1 |
| Durdu, Y | 1 |
| Güleç, N | 1 |
| Islim, F | 1 |
| Biçer, M | 1 |
| Hall, RL | 1 |
| Partridge, R | 1 |
| Venkatraman, N | 1 |
| Wiselka, M | 1 |
| Breck, RW | 1 |
| Vitkauskiene, A | 1 |
| Sakalauskas, R | 1 |
| Dudzevicius, V | 1 |
| West, M | 1 |
| Boulanger, BR | 1 |
| Fogarty, C | 1 |
| Tennenberg, A | 1 |
| Wiesinger, B | 1 |
| Oross, M | 1 |
| Wu, SC | 2 |
| Fowler, C | 1 |
| Morgan, N | 1 |
| Kahn, JB | 1 |
| Tarr, PE | 1 |
| Stock, F | 1 |
| Cooke, RH | 1 |
| Fedorko, DP | 1 |
| Lucey, DR | 1 |
| Beovic, B | 1 |
| Matos, B | 1 |
| Bosnjak, R | 1 |
| Seme, K | 1 |
| Mueller-Premru, M | 1 |
| Hergouth-Krizan, V | 1 |
| Cizman, M | 1 |
| Finsterer, J | 1 |
| Kotzailias, N | 1 |
| Illinger, J | 1 |
| Mohammedi, I | 1 |
| Martin, O | 1 |
| Argaud, L | 1 |
| St Denis, M | 1 |
| Robert, D | 1 |
| Fujita, M | 1 |
| Ishibashi, T | 1 |
| Hara, N | 1 |
| Yoshida, M | 1 |
| Yamada, H | 1 |
| Luyt, CE | 1 |
| Chastre, J | 1 |
| Fagon, JY | 1 |
| Sokolova, VI | 1 |
| Orlov, VA | 1 |
| Surkova, IuV | 1 |
| Shenderovich, VA | 1 |
| Smirnova, LB | 1 |
| Shorr, AF | 1 |
| Susla, GB | 1 |
| Kollef, MH | 2 |
| Okimoto, N | 3 |
| Yamato, K | 3 |
| Honda, Y | 3 |
| Kurihara, T | 3 |
| Osaki, K | 3 |
| Asaoka, N | 3 |
| Fujita, K | 1 |
| Ohba, H | 1 |
| Cantón, R | 1 |
| Cobos, N | 1 |
| de Gracia, J | 1 |
| Baquero, F | 1 |
| Honorato, J | 1 |
| Gartner, S | 1 |
| Alvarez, A | 1 |
| Salcedo, A | 1 |
| Oliver, A | 1 |
| García-Quetglas, E | 1 |
| Sun, HK | 1 |
| Kuti, JL | 1 |
| Nicolau, DP | 1 |
| Bassaris, HP | 1 |
| Chrysanthopoulos, CJ | 1 |
| Skouelis, AT | 1 |
| Starakis, JC | 1 |
| Brückner, O | 1 |
| Trautmann, M | 1 |
| Engelhardt, D | 1 |
| Ruckdeschel, G | 1 |
| Beuscart, C | 1 |
| Leroy, O | 1 |
| Chidiac, C | 2 |
| Houriez, S | 1 |
| Caillaux, M | 1 |
| Beaucaire, G | 2 |
| Mouton, Y | 1 |
| Flanagan, MC | 1 |
| Mitchell, ES | 1 |
| Haigney, MC | 1 |
| Mouzopoulos, G | 1 |
| Stamatakos, M | 1 |
| Vasiliadis, G | 1 |
| Skandalakis, P | 1 |
| Allan, RC | 1 |
| Moghal, M | 1 |
| Wijesuriya, V | 1 |
| Melzer, M | 1 |
| Steward, J | 1 |
| Piercy, T | 1 |
| Lever, MS | 1 |
| Simpson, AJ | 1 |
| Brooks, TJ | 1 |
| Tennenberg, AM | 1 |
| Davis, NB | 1 |
| Kahn, J | 1 |
| Kawai, S | 1 |
| Nakagawa, T | 1 |
| Sakayori, S | 1 |
| Kobayashi, O | 1 |
| Kamiya, S | 1 |
| Wang, CY | 1 |
| Chuang, YM | 1 |
| Teng, LJ | 1 |
| Yang, PC | 1 |
| Kuo, SH | 1 |
| Hsueh, PR | 1 |
| Wegerle, S | 1 |
| Markus, A | 1 |
| Weber, N | 1 |
| Steffen, H | 1 |
| King, B | 1 |
| Eder, W | 1 |
| Philipp, E | 1 |
| Morresi-Hauff, A | 1 |
| Häussinger, K | 1 |
| Hoffmann, H | 1 |
| Papp, M | 1 |
| Farkas, A | 1 |
| Udvardy, M | 1 |
| Tornai, I | 1 |
| Leone, S | 1 |
| Fiore, M | 1 |
| Felaco, FM | 1 |
| Esposito, S | 1 |
| Rikimaru, T | 1 |
| Yonemitu, J | 1 |
| Koga, T | 1 |
| Shimada, A | 1 |
| Yokoyama, T | 1 |
| Kawayama, T | 1 |
| Kamimura, T | 1 |
| Aizawa, H | 1 |
| Nanba, F | 2 |
| Kibayashi, T | 2 |
| Kishimoto, M | 2 |
| Tsifansky, MD | 1 |
| Yeo, Y | 1 |
| Evgenov, OV | 1 |
| Bellas, E | 1 |
| Benjamin, J | 1 |
| Kohane, DS | 1 |
| Ryan, RJ | 1 |
| Lindsell, C | 1 |
| Sheehan, P | 1 |
| Yu, L | 1 |
| Chen, YL | 1 |
| Zhu, YJ | 1 |
| Wang, JX | 1 |
| Liu, YN | 1 |
| Dunn, M | 1 |
| Wunderink, RG | 1 |
| Roussel-Delvallez, M | 1 |
| Lucena, MI | 1 |
| Marquez, M | 1 |
| Velasco, JL | 1 |
| Andrade, RJ | 1 |
| Ciofu, O | 1 |
| Giwercman, B | 1 |
| Pedersen, SS | 1 |
| Høiby, N | 1 |
| Wood, CA | 1 |
| Counsell, R | 1 |
| Pratt, J | 1 |
| Williams, MV | 1 |
| Siami, GA | 1 |
| Wilkins, WT | 1 |
| Bess, DT | 1 |
| Christman, JW | 1 |
| Asnis, DS | 1 |
| Bresciani, AR | 1 |
| Cohn, M | 1 |
| Heurlin, N | 1 |
| Bergström, SE | 1 |
| Winiarski, J | 1 |
| Ringden, O | 1 |
| Ljungman, P | 1 |
| Lönnqvist, B | 1 |
| Andersson, J | 1 |
| Alemany Francés, ML | 1 |
| Romero Candeira, S | 1 |
| Fernández Aracil, C | 1 |
| Masuda, N | 1 |
| Takahashi, Y | 1 |
| Otsuki, M | 1 |
| Ibuki, E | 1 |
| Miyoshi, H | 1 |
| Nishino, T | 1 |
| Hachem, R | 1 |
| Raad, I | 1 |
| Rolston, KV | 1 |
| Whimbey, E | 1 |
| Katz, R | 1 |
| Tarrand, J | 1 |
| Libshitz, H | 1 |
| Marklein, G | 1 |
| Church, DA | 2 |
| Kanga, JF | 1 |
| Kuhn, RJ | 2 |
| Rubio, TT | 2 |
| Spohn, WA | 1 |
| Stevens, JC | 1 |
| Painter, BG | 1 |
| Thurberg, BE | 1 |
| Haverstock, DC | 1 |
| Perroncel, RY | 1 |
| Echols, RM | 2 |
| Miles, MV | 1 |
| Lettieri, JT | 1 |
| Macías, J | 1 |
| Pineda, JA | 1 |
| Borderas, F | 1 |
| Gallardo, JA | 1 |
| Delgado, J | 1 |
| Leal, M | 1 |
| Sánchez-Quijano, A | 1 |
| Lissen, E | 1 |
| Bloch, KC | 1 |
| Nadarajah, R | 1 |
| Jacobs, R | 1 |
| Hyatt, JM | 1 |
| Luzier, AB | 1 |
| Forrest, A | 1 |
| Ballow, CH | 1 |
| Schentag, JJ | 1 |
| Chuchalin, AG | 1 |
| Novikov, IuK | 1 |
| Avdeev, SN | 1 |
| Belevskiĭ, AS | 1 |
| Vlasnik, J | 1 |
| Sharpless, L | 1 |
| Pasque, C | 1 |
| Murphy, D | 1 |
| Fraser, V | 1 |
| Baraia-Etxaburu, J | 1 |
| Malero, P | 1 |
| Unzaga, MJ | 1 |
| Teira, R | 1 |
| Muñoz, J | 1 |
| Cisterna, R | 1 |
| Santamaría, JM | 1 |
| Ernst, A | 1 |
| Gordon, FD | 1 |
| Hayek, J | 1 |
| Silvestri, RC | 1 |
| Koziel, H | 1 |
| Periti, P | 1 |
| Mazzei, T | 1 |
| Curti, ME | 1 |
| Manhold, C | 1 |
| von Rolbicki, U | 1 |
| Brase, R | 1 |
| Timm, J | 1 |
| von Pritzbuer, E | 1 |
| Heimesaat, M | 1 |
| Kljucar, S | 1 |
| Debord, T | 1 |
| Vidal, D | 1 |
| Krumpe, PE | 1 |
| Cohn, S | 1 |
| Garreltes, J | 1 |
| Ramirez, J | 1 |
| Coulter, H | 1 |
| Haverstock, D | 1 |
| Echols, R | 1 |
| Caldwell, JW | 1 |
| Singh, S | 1 |
| Johnson, RH | 1 |
| Vikram, HR | 1 |
| Shore, ET | 1 |
| Venkatesh, PR | 1 |
| Sefton, AM | 1 |
| Maskell, JP | 1 |
| Williams, JD | 1 |
| Robert, R | 1 |
| Grollier, G | 1 |
| Doré, P | 1 |
| Hira, M | 1 |
| Ferrand, E | 1 |
| Fauchère, JL | 1 |
| Thadepalli, H | 1 |
| Reddy, U | 1 |
| Chuah, SK | 1 |
| Hanna, N | 1 |
| Rana, G | 1 |
| Gollapudi, S | 1 |
| Breen, D | 1 |
| Schonell, M | 1 |
| Au, T | 1 |
| Reiss-Levy, E | 1 |
| Pillai, A | 1 |
| Mitchell, JL | 1 |
| Hill, SL | 1 |
| Stockley, RA | 1 |
| Gruson, D | 1 |
| Hilbert, G | 1 |
| Vargas, F | 1 |
| Valentino, R | 1 |
| Bebear, C | 2 |
| Allery, A | 1 |
| Gbikpi-Benissan, G | 1 |
| Cardinaud, JP | 1 |
| Torres, A | 1 |
| Bauer, TT | 1 |
| León-Gil, C | 1 |
| Castillo, F | 1 |
| Alvarez-Lerma, F | 1 |
| Martínez-Pellús, A | 1 |
| Leal-Noval, SR | 1 |
| Nadal, P | 1 |
| Palomar, M | 1 |
| Blanquer, J | 1 |
| Ros, F | 1 |
| Join-Lambert, OF | 1 |
| Michéa-Hamzehpour, M | 1 |
| Köhler, T | 1 |
| Chau, F | 1 |
| Faurisson, F | 1 |
| Dautrey, S | 1 |
| Vissuzaine, C | 1 |
| Carbon, C | 1 |
| Pechère, J | 1 |
| Costa, SF | 1 |
| Newbaer, M | 1 |
| Santos, CR | 1 |
| Basso, M | 1 |
| Soares, I | 1 |
| Levin, AS | 1 |
| Kronvall, G | 1 |
| Bakker-Woudenberg, IA | 1 |
| ten Kate, MT | 1 |
| Guo, L | 1 |
| Working, P | 1 |
| Mouton, JW | 1 |
| Montgomery, MJ | 1 |
| Beringer, PM | 1 |
| Aminimanizani, A | 1 |
| Louie, SG | 1 |
| Shapiro, BJ | 1 |
| Jelliffe, R | 1 |
| Gill, MA | 1 |
| Kaneko, Y | 1 |
| Kuroki, M | 1 |
| Ohi, H | 1 |
| Miyazaki, Y | 1 |
| Higashiyama, Y | 1 |
| Hirakata, Y | 1 |
| Tomono, K | 1 |
| Kadota, JI | 1 |
| Biechy, M | 1 |
| Gálvez, E | 1 |
| Salgueró, E | 1 |
| Báñez, F | 1 |
| Debon, R | 1 |
| Breilh, D | 1 |
| Boselli, E | 1 |
| Saux, MC | 1 |
| Duflo, F | 1 |
| Chassard, D | 1 |
| Allaouchiche, B | 1 |
| Trübel, HK | 1 |
| Meyer, HG | 1 |
| Jahn, B | 1 |
| Knuf, M | 1 |
| Kamin, W | 1 |
| Huth, RG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Open Label Study to Compare the Safety and Efficacy of Levofloxacin With That of Imipenem/Cilastatin in the Treatment of Nosocomial Pneumonia[NCT00236834] | Phase 3 | 438 participants (Actual) | Interventional | 1997-12-31 | Completed | ||
| Impact of Aggressive Empiric Antibiotic Therapy and Duration of Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Hospitalized Subjects With Pneumonia Requiring Mechanical Ventilation[NCT01570192] | Phase 2 | 43 participants (Actual) | Interventional | 2010-09-30 | Terminated (stopped due to NIAID terminated the study due to low subject enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 2 |
| MEGroup - Meropenem Only | 8 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 2 |
| m-MITT Group - Meropenem Only | 8 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 1 |
| ME Group - Meropenem Only | 2 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 1 |
| m-MITT Group - Meropenem Only | 2 |
Percentage of patients who died by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 1 |
| ME Group - Meropenem Only | 0 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 2 |
| m-MITT Group - Meropenem Only | 2 |
Percentage of patients who died by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 2 |
| ME Group - Meropenem Only | 1 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 3 |
| m-MITT Group - Meropenem Only | 3 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: Day 5/Early Extubation
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 3 |
| ME Group - Meropenem Only | 6 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 3 |
| m-MITT Group - Meropenem Only | 7 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 2 |
| ME Group - Meropenem Only | 6 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 2 |
| m-MITT Group - Meropenem Only | 7 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 3 |
| ME Group - Meropenem Only | 9 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 3 |
| m-MITT Group - Meropenem Only | 11 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: Day 5/Early Extubation
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 1 |
| ME Group - Meropenem Only | 1 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 1 |
| m-MITT Group - Meropenem Only | 2 |
The emergence of resistance is defined as a change of meropenem MIC or aminoglycoside MIC by two tube dilutions (fourfold) from baseline when assessed at the second BAL procedure on day 5/early extubation. Patients are evaluable for this endpoint IF they had baseline BAL and Day 5/early extubation and if they had positive cultures on baseline and Day/EE. (NCT01570192)
Timeframe: up to 28 days after enrollment
| Intervention | participants (Number) | |
|---|---|---|
| suppression of emergence of resistance | emergence of resistance | |
| I.V. Meropenem | 5 | 1 |
10 reviews available for ciprofloxacin and Bacterial Pneumonia
| Article | Year |
|---|---|
[A case of repeated upper gastrointestinal bleeding secondary to Legionella pneumonia].
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Female; Gastrointestinal Hemorrhage; Humans; Legionnaire | 2011 |
Quinolones for treatment of nosocomial pneumonia: a meta-analysis.
Topics: Anti-Infective Agents; Cilastatin; Ciprofloxacin; Cross Infection; Humans; Imipenem; Levofloxacin; M | 2005 |
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bronchopneumonia; Cefepime; Ceftazidime; Cep | 2005 |
Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Re | 2006 |
[Bacterial infections in liver cirrhosis].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ascites; | 2007 |
[Early and timely therapy: when to interrupt antibiotic therapy in nosocomial acquired pneumonia?].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cohort Studies; Cross Infection; Drug Administration Schedule; | 2007 |
Ventilator-associated pneumonia caused by Pseudomonas infection.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactam Resistance; Ciprofloxacin; Drug Resistance, Micr | 1995 |
Chryseobacterium meningosepticum: an emerging pathogen among immunocompromised adults. Report of 6 cases and literature review.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotics, Antitubercular; Breast Neoplasms; Ciprofloxacin; Dr | 1997 |
Lung abcess complicating Legionella micdadei pneumonia in an adult liver transplant recipient: case report and review.
Topics: Adult; Anti-Infective Agents; Bronchoalveolar Lavage Fluid; Ciprofloxacin; Diabetes Mellitus, Type 2 | 1998 |
[Pulmonary anthrax].
Topics: Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Doxycycline; Humans; Pneumonia | 1998 |
19 trials available for ciprofloxacin and Bacterial Pneumonia
| Article | Year |
|---|---|
Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study.
Topics: Adult; Aged; Anti-Bacterial Agents; Cilastatin; Ciprofloxacin; Cross Infection; Drug Therapy, Combin | 2003 |
Value of the clinical pulmonary infection score for the identification and management of ventilator-associated pneumonia.
Topics: Algorithms; Anti-Infective Agents; Bronchoscopy; Ciprofloxacin; Female; France; Humans; Intensive Ca | 2004 |
[Therapy of bronchopulmonary infection in smokers].
Topics: Adult; Aged; Anti-Bacterial Agents; Bronchitis, Chronic; Ciprofloxacin; Colony Count, Microbial; Com | 2004 |
Clinical effect of intravenous ciprofloxacin on hospital-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bac | 2005 |
[Clinical effects of intravenous ciprofloxacin on community-acquired pneumonia with positive Immunocard Mycoplasma test results].
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Biomarkers; Ciprofloxacin; Community-Acquired | 2008 |
Comparison of ciprofloxacin with imipenem in the treatment of severe pneumonia in hospitalised geriatric patients.
Topics: Aged; Anti-Infective Agents; APACHE; Ciprofloxacin; Double-Blind Method; Hospitalization; Humans; Im | 1995 |
Quinolones in everyday clinical practice: respiratory tract infections and nosocomial pneumonia.
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Double-Blind Method; Female; Fle | 1996 |
Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
Topics: Acute Disease; Adolescent; Anti-Infective Agents; Arthralgia; Ceftazidime; Child; Child, Preschool; | 1997 |
Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation.
Topics: Acute Disease; Administration, Oral; Adolescent; Anti-Infective Agents; Biological Availability; Chi | 1997 |
Modeling the response of pneumonia to antimicrobial therapy.
Topics: Anti-Infective Agents; Cefmenoxime; Ceftazidime; Cephalosporins; Ciprofloxacin; Clinical Trials as T | 1997 |
[Effectiveness of ciprofloxacin in the treatment of hospital infections of the lower respiratory tract].
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Bronchiectasis; Bronchitis; Ch | 1997 |
Efficacy and safety of high dose intravenous ciprofloxacin in the treatment of bacterial pneumonia. Italian Ciprofloxacin Study Group.
Topics: Anti-Infective Agents; Ciprofloxacin; Female; Humans; Injections, Intravenous; Male; Pneumonia, Bact | 1998 |
Outbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective, randomized study.
Topics: Adult; Anti-Infective Agents; APACHE; Ceftazidime; Cephalosporins; Ciprofloxacin; Cross Infection; D | 1998 |
[The clinical manifestation and drug sensitive tests of lower respiratory tract infection by enterobacter cloacae. The Pulmonary Infection and Fibrosis Group, Thoracic Society Shanghai Medical Association].
Topics: Adult; Aged; Amikacin; Anti-Infective Agents; Ciprofloxacin; Drug Therapy, Combination; Enterobacter | 1997 |
Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Ag | 1999 |
Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cost-Benefit Analysis; Cross Infection; Double-Blind Me | 1999 |
Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin.
Topics: Adult; Aged; Anti-Infective Agents; Cilastatin; Ciprofloxacin; Cross Infection; Drug Resistance, Mic | 2000 |
Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Topics: Adult; Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Cystic Fibrosis; Female; Genotype; Ha | 2001 |
Pharmacokinetic parameters of ciprofloxacin (500 mg/5 mL) oral suspension in critically ill patients with severe bacterial pneumonia: a comparison of two dosages.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Biological Availability | 2002 |
74 other studies available for ciprofloxacin and Bacterial Pneumonia
| Article | Year |
|---|---|
Novel Broad-Spectrum Antimicrobial Peptide Derived from Anoplin and Its Activity on Bacterial Pneumonia in Mice.
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Antineoplastic Agents; Cell Line; C | 2021 |
Expression of T9W in Pichia pastoris and the protective roles of T9W in ICR Mice.
Topics: Animals; Anti-Infective Agents; Antimicrobial Cationic Peptides; Ciprofloxacin; Disease Models, Anim | 2020 |
Topics: Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ciprofloxacin; Cl | 2020 |
Pneumonia with pleural empyema caused by Salmonella Typhi in an immunocompetent child living in a non-endemic country.
Topics: Adolescent; Anti-Bacterial Agents; Ceftriaxone; Ciprofloxacin; Drainage; Empyema, Pleural; Female; F | 2018 |
Association between oral fluoroquinolone use and lateral canthal tendon rupture: case report.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Blepharoplasty; Ciprofloxacin; Conjunctival Dise | 2018 |
[Nocardia pseudobrasiliensis pneumonia in a heart transplant recipient].
Topics: Acetamides; Adult; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Heart Transplantation; Human | 2013 |
Impact of qnrA1, qnrB1 and qnrS1 on the efficacy of ciprofloxacin and levofloxacin in an experimental pneumonia model caused by Escherichia coli with or without the GyrA mutation Ser83Leu.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; Drug Resistance, | 2013 |
PrtR homeostasis contributes to Pseudomonas aeruginosa pathogenesis and resistance against ciprofloxacin.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Bacterial Proteins; Biofilms; Bronchoalveolar Lavage | 2014 |
Population pharmacokinetic analysis of ciprofloxacin in the elderly patients with lower respiratory tract infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; | 2014 |
Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; | 2015 |
Pneumonic tularemia presenting with a vesicular eruption.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Female; Francisella tularensis; Humans; Pneumonia, Bact | 2015 |
No development of ciprofloxacin resistance in the Haemophilus species associated with pneumonia over a 10-year study.
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Multiple, Bacterial; F | 2015 |
Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Colony Count, Microbial; Drug Res | 2008 |
Efficient drug delivery to alveolar macrophages and lung epithelial lining fluid following pulmonary administration of liposomal ciprofloxacin in rats with pneumonia and estimation of its antibacterial effects.
Topics: Animals; Anti-Infective Agents; Bacteria; Ciprofloxacin; Epithelium; Liposomes; Lung; Macrophages, A | 2008 |
Severe pneumonia caused by ciprofloxacin resistant panton-valentine leukocidin producing community acquired meticillin resistant Staphylococcus aureus.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Bacterial Toxins; Ciprofloxacin; Community-Acquired Infect | 2009 |
[A rare agent of pneumonia: Brucella melitensis].
Topics: Anti-Infective Agents; Brucella melitensis; Brucellosis; Ciprofloxacin; Cough; Diagnosis, Differenti | 2008 |
In vivo efficacy of sitafloxacin in a new murine model of non-typeable Haemophilus influenzae pneumonia by sterile intratracheal tube.
Topics: Animals; Anti-Bacterial Agents; Bronchioles; Ciprofloxacin; Disease Models, Animal; Fluoroquinolones | 2009 |
Cavitary pneumonia and skin lesions.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Ciprofloxacin; Female; H | 2012 |
Meningitis and pneumonitis caused by pet rodents.
Topics: Adult; Animals; Anti-Bacterial Agents; C-Reactive Protein; Ceftriaxone; Ciprofloxacin; Female; Fusob | 2012 |
[Neonatal infection with Stenotrophomonas maltophilia (2 case studies)].
Topics: Amikacin; Anti-Bacterial Agents; Brain Abscess; Chloramphenicol; Ciprofloxacin; Cross Infection; Dru | 2012 |
[A rare cause of pneumonia: Shewanella putrefaciens].
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Bronchiectasis; Ceftazidime; Ceftriaxone; Cipro | 2012 |
Invasive non-typhoidal salmonella infection with multifocal seeding in an immunocompetent host: an emerging disease in the developed world.
Topics: Abscess; Anti-Bacterial Agents; Ceftriaxone; Ciprofloxacin; Communicable Diseases, Emerging; Diagnos | 2013 |
"Ciprofloxacin: a warning for clinicians".
Topics: Achilles Tendon; Anti-Infective Agents; Ciprofloxacin; Haemophilus Infections; Haemophilus influenza | 2002 |
[The impact of antibiotic use on hospital-acquired pneumonia: data of etiology tests].
Topics: Acinetobacter; Acinetobacter Infections; Amikacin; Ampicillin; Anti-Bacterial Agents; Anti-Infective | 2003 |
Multidrug-resistant Corynebacterium striatum pneumonia in a heart transplant recipient.
Topics: Amphotericin B; Ciprofloxacin; Corynebacterium; Corynebacterium Infections; Drug Resistance, Multipl | 2003 |
Prevention of nosocomial lower respiratory tract infections in patients after intracranial artery aneurysm surgery with a short course of antimicrobials.
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Female; Humans; Intracranial Aneurysm; Male; | 2003 |
Thrombocytosis under ciprofloxacin and tazobactam/piperacillin.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Therapy, Combination; Humans; Male; Middle Aged; Penicill | 2003 |
[Community-acquired Pseudomonas aeruginosa bacteremic pneumonia in a "healthy" subject].
Topics: Adult; Anti-Infective Agents; Bacteremia; Bronchoalveolar Lavage; Ciprofloxacin; Community-Acquired | 2003 |
[The effect of intravenous ciprofloxacin for community acquired pneumonia in adults].
Topics: Anti-Infective Agents; Ciprofloxacin; Community-Acquired Infections; Drug Administration Schedule; F | 2003 |
Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Cross Infection; Dose-R | 2005 |
Follow-up therapy with ciprofloxacin in severe infection, an alternative to parenteral treatment.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial I | 1989 |
Efficacy and safety in the oral treatment of purulent chest disease and pneumonia with cefixime, ofloxacin, and ciprofloxacin.
Topics: Administration, Oral; Anti-Bacterial Agents; Bronchitis; Cefixime; Ciprofloxacin; Clinical Trials as | 1989 |
Effect of combination therapy with ciprofloxacin and azlocillin in intensive care patients with pneumonia and/or sepsis.
Topics: Anti-Bacterial Agents; Azlocillin; Bacteria; Ciprofloxacin; Clinical Trials as Topic; Critical Care; | 1989 |
Treatment of bronchopulmonary infections by ciprofloxacin in an intensive care unit. Correlation between serum and bronchial concentrations and bacteriological results.
Topics: Anti-Bacterial Agents; Bronchopneumonia; Ciprofloxacin; Humans; Intensive Care Units; Pneumonia, Bac | 1989 |
Ciprofloxacin-induced torsade de pointes.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Defibrillators, Implantable; Electrocardiography; Follo | 2006 |
Rupture of adductor longus tendon due to ciprofloxacin.
Topics: Adult; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Stud | 2005 |
University-acquired pneumonia.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Cefuroxime; Ciprofloxacin; Community-Acquired Infections; | 2006 |
Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin | 2006 |
Effect of ciprofloxacin on levels of lipopolysaccharide and cytokines in experimentally induced gram-negative bacterial pneumonia in mice.
Topics: Animals; Anti-Infective Agents; Bronchoalveolar Lavage Fluid; Ciprofloxacin; Cytokines; Klebsiella I | 2006 |
Bacteraemic pneumonia caused by Neisseria lactamica with reduced susceptibility to penicillin and ciprofloxacin in an adult with liver cirrhosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Bacteremia; Base Sequence; Ceftriaxone; Ciprofl | 2006 |
[Pulmonary nocardiosis with trimethoprime/sulphamethoxazole-resistant Nocardia paucivorans in a patient with no signs of immunosuppression].
Topics: Amoxicillin-Potassium Clavulanate Combination; Ciprofloxacin; Drug Resistance, Bacterial; Drug Thera | 2007 |
[Comparison of ciprofloxacin with biapenem in patients with moderate or severe pneumonia].
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Male; Pneumonia, Bacterial; Thienamycins | 2007 |
[Study of the cases with multidrug-resistant Pseudomonas aeruginosa by sputum culture].
Topics: Adult; Aged; Amikacin; Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Drug Combin | 2007 |
Microparticles for inhalational delivery of antipseudomonal antibiotics.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchitis; Ceftazidime; Chromatography, High Pre | 2008 |
Fluoroquinolone resistance during 2000-2005: an observational study.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Community-Acquired Infec | 2008 |
[Clinical analysis of 60 cases of nosocomal pneumonias].
Topics: Adult; Ciprofloxacin; Cross Infection; Humans; Klebsiella Infections; Klebsiella pneumoniae; Pneumon | 1994 |
[Antibiotic treatment for pneumonia caused by Flavobacterium meningosepticum].
Topics: Aged; Aztreonam; Cefsulodin; Ciprofloxacin; Drug Therapy, Combination; Female; Flavobacterium; Gram- | 1994 |
Should Pseudomonas aeruginosa isolates resistant to one of the fluorinated quinolones be tested for the others? Studies with an experimental model of pneumonia.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Lung; Male; Microbial Sen | 1995 |
Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome.
Topics: Acute Kidney Injury; Adult; AIDS-Related Opportunistic Infections; Ciprofloxacin; Humans; Male; Pneu | 1995 |
Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbenicillin; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; | 1994 |
Treatment of severe pneumonia with ciprofloxacin or imipenem.
Topics: Ciprofloxacin; Humans; Imipenem; Pneumonia, Bacterial | 1994 |
Chemotherapy for germ cell tumours: prophylactic ciprofloxacin reduces the incidence of neutropenic fever.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carbo | 1994 |
Mycobacterium avium-intracellulare complex pneumonia in a non-HIV-infected individual: an increasingly recognized disease.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antitubercular Age | 1996 |
Fungal pneumonia: the predominant lung infection causing death in children undergoing bone marrow transplantation.
Topics: Adolescent; Amphotericin B; Antibodies, Monoclonal; Antifungal Agents; Aspergillus fumigatus; Bone M | 1996 |
[Spontaneous bilateral pneumothorax].
Topics: Administration, Oral; Aged; Anti-Infective Agents; Bronchography; Ciprofloxacin; Female; Humans; Pne | 1996 |
In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Evaluation, Preclinical; F | 1996 |
Cutaneous and pulmonary infections caused by Mycobacterium vaccae.
Topics: Aged; Animals; Anti-Bacterial Agents; Cattle; Ciprofloxacin; Humans; Male; Middle Aged; Minocycline; | 1996 |
Rhodococcus or mycobacterium? An example of misdiagnosis in HIV infection.
Topics: Actinomycetales Infections; Adult; AIDS-Related Opportunistic Infections; Ciprofloxacin; Clarithromy | 1997 |
Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteremia; Ceftazidime; Cephalos | 1997 |
[Pneumonia caused by Rhodococcus equi in patients with AIDS: difficulty in defining the most appropriate initial treatment].
Topics: Actinomycetales Infections; Adult; AIDS-Related Opportunistic Infections; Ciprofloxacin; Clarithromy | 1997 |
Community acquired Pseudomonas aeruginosa pneumonia.
Topics: Anti-Infective Agents; Ciprofloxacin; Community-Acquired Infections; Humans; Male; Middle Aged; Pneu | 1999 |
Selection of resistant variants of respiratory pathogens by quinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Haemophilus influenzae; Humans; Le | 1999 |
Nosocomial pneumonia with isolation of anaerobic bacteria in ICU patients: therapeutic considerations and outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteria, Anaerobic; Cefotaxime; | 1999 |
Evaluation of trovafloxacin in the treatment of Klebsiella pneumoniae lung infection in tumour-bearing mice.
Topics: Animals; Anti-Infective Agents; Antibiotics, Antineoplastic; Ciprofloxacin; Daunorubicin; Drug Evalu | 2000 |
Pasteurella multocida: a case report of bacteremic pneumonia and 10-year laboratory review.
Topics: Aged; Animals; Ceftriaxone; Cephalosporins; Ciprofloxacin; Dogs; Humans; Male; Pasteurella Infection | 2000 |
A case of Haemophilus parainfluenzae pneumonia.
Topics: Adult; Anti-Infective Agents; Antibodies, Bacterial; Blood Sedimentation; C-Reactive Protein; Ciprof | 2000 |
Rotation and restricted use of antibiotics in a medical intensive care unit. Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria.
Topics: Aged; Antibiotic Prophylaxis; Ceftazidime; Ciprofloxacin; Critical Care; Cross Infection; Cross-Sect | 2000 |
Differential selection of multidrug efflux mutants by trovafloxacin and ciprofloxacin in an experimental model of Pseudomonas aeruginosa acute pneumonia in rats.
Topics: Acute Disease; Animals; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Drug Resis | 2001 |
Nosocomial pneumonia: importance of recognition of aetiological agents to define an appropriate initial empirical therapy.
Topics: Anti-Bacterial Agents; Bacteria; Blood; Bronchoalveolar Lavage Fluid; Ciprofloxacin; Cross Infection | 2001 |
MIC determination of fusidic acid and of ciprofloxacin using multidisk diffusion tests.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Fusidic Acid; Gram-Negative Bacteria; G | 2000 |
Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Drug Carriers; Drug Delivery | 2001 |
Effects of parenterally administered ciprofloxacin in a murine model of pulmonary Pseudomonas aeruginosa infection mimicking ventilator-associated pneumonia.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Cefozopran; Cephalosporins; Cilastatin; Ciprofloxa | 2001 |
[Soft-tissue abscess caused by Rhodococcus equi in a patient on hemodialysis].
Topics: Abscess; Actinomycetales Infections; Adrenal Cortex Hormones; Aged; Amikacin; Anti-Glomerular Baseme | 2001 |
Complicated nosocomial pneumonia due to Legionella pneumophila in an immunocompromised child.
Topics: Anti-Bacterial Agents; Child, Preschool; Ciprofloxacin; Clarithromycin; Cross Infection; Drug Resist | 2002 |